Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application

Following receipt yesterday evening of additional data, an exceptional meeting has been scheduled for 21 December to conclude if possible. The meeting planned for 29 December will be maintained if needed

Source:

European Medicines Agency